Recent years have been marked by serious breakthroughs in the drug therapy of malignant neoplasms. The results of new successful studies are received almost constantly, which affect both clinical practice and the fate of patients. The studies in oncourology are also actively conducted: over the past 12 months, another batch of data from clinical studies has been obtained, in particular, comparing various combinations of chemotherapy drugs, the possibilities of combined targeted and immune therapy. The article deals with issues related to the treatment of metastatic renal cell carcinoma, urothelial cancer, the use of radiopharmaceuticals in the treatment of castration-resistant prostate cancer, as well as adjuvant therapy of urothelial cancer, which has not yet found an unambiguous solution. Phases II and III data of clinical trials in combination with the leading experts’ opinions should help to improve the approach to the treatment of oncourology diseases, especially in the late stages. KEYWORDS: renal cell carcinoma, urothelial cancer, metastatic castration-resistant prostate cancer, immunotargeting therapy, chemotherapy, adverse events. FOR CITATION: Solodkiy V.A., Pavlov R.A.,
📖 افتح في inklap 🔗 DOI 📮 اطلب بحثاً